The present invention relates to sustained release dosage form of Ranolazine or pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), enantiomer(s) thereof which comprises a combination of atleast two pH-dependent binders and optionally one or more pharmaceutically acceptable excipient(s).